Bank of New York Mellon’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.71M | Buy |
96,061
+89,464
| +1,356% | +$6.55M | ﹤0.01% | 2265 |
|
|
2026
Q1 | $475K | Buy |
+6,597
| New | +$376K | ﹤0.01% | 3635 |
|
|
2025
Q4 | – | Sell |
-4,327
| Closed | -$246K | – | 4251 |
|
|
2025
Q3 | $246K | Buy |
+4,327
| New | +$143K | ﹤0.01% | 3941 |
|
|
2025
Q2 | – | Sell |
-26,220
| Closed | -$267K | – | 4224 |
|
|
2025
Q1 | $267K | Sell |
26,220
-1,134
| -4% | -$14.8K | ﹤0.01% | 3756 |
|
|
2024
Q4 | $382K | Hold |
27,354
| – | – | ﹤0.01% | 3660 |
|
|
2024
Q3 | $533K | Sell |
27,354
-9,415
| -26% | -$179K | ﹤0.01% | 3485 |
|
|
2024
Q2 | $684K | Buy |
36,769
+35,511
| +2,823% | +$748K | ﹤0.01% | 3394 |
|
|
2024
Q1 | $17.6K | Sell |
1,258
-4,435
| -78% | -$46.4K | ﹤0.01% | 4115 |
|
|
2023
Q4 | $48.3K | Sell |
5,693
-191
| -3% | -$1.45K | ﹤0.01% | 4159 |
|
|
2023
Q3 | $52.6K | Sell |
5,884
-2,529
| -30% | -$24.3K | ﹤0.01% | 4159 |
|
|
2023
Q2 | $72.6K | Sell |
8,413
-98,001
| -92% | -$1.04M | ﹤0.01% | 4121 |
|
|
2023
Q1 | $1.12M | Sell |
106,414
-2,346
| -2% | -$71K | ﹤0.01% | 3086 |
|
|
2022
Q4 | $3.69M | Sell |
108,760
-5,872
| -5% | -$284K | ﹤0.01% | 2514 |
|
|
2022
Q3 | $5.5M | Buy |
114,632
+2,021
| +2% | +$120K | ﹤0.01% | 2244 |
|
|
2022
Q2 | $6.42M | Sell |
112,611
-6,772
| -6% | -$427K | ﹤0.01% | 2183 |
|
|
2022
Q1 | $9.65M | Buy |
119,383
+5,870
| +5% | +$869K | ﹤0.01% | 2084 |
|
|
2021
Q4 | $23M | Sell |
113,513
-1,046
| -0.9% | -$227K | ﹤0.01% | 1642 |
|
|
2021
Q3 | $30.9M | Sell |
114,559
-688
| -0.6% | -$165K | 0.01% | 1458 |
|
|
2021
Q2 | $29.7M | Buy |
115,247
+443
| +0.4% | +$123K | 0.01% | 1504 |
|
|
2021
Q1 | $34.4M | Sell |
114,804
-734
| -0.6% | -$228K | 0.01% | 1367 |
|
|
2020
Q4 | $29.5M | Sell |
115,538
-3,942
| -3% | -$1.02M | 0.01% | 1392 |
|
|
2020
Q3 | $29.7M | Sell |
119,480
-4,382
| -4% | -$1.38M | 0.01% | 1204 |
|
|
2020
Q2 | $43M | Buy |
123,862
+3,831
| +3% | +$1.2M | 0.01% | 972 |
|
|
2020
Q1 | $32.1M | Sell |
120,031
-2,055
| -2% | -$636K | 0.01% | 1002 |
|
|
2019
Q4 | $39.5M | Buy |
122,086
+23,075
| +23% | +$6.69M | 0.01% | 1125 |
|
|
2019
Q3 | $27.1M | Buy |
99,011
+385
| +0.4% | +$141K | 0.01% | 1341 |
|
|
2019
Q2 | $52.6M | Buy |
98,626
+2,345
| +2% | +$1.18M | 0.01% | 946 |
|
|
2019
Q1 | $48.5M | Buy |
96,281
+1,701
| +2% | +$1.01M | 0.01% | 972 |
|
|
2018
Q4 | $46.6M | Buy |
94,580
+1,178
| +1% | +$711K | 0.01% | 939 |
|
|
2018
Q3 | $85.4M | Buy |
93,402
+16,074
| +21% | +$13.7M | 0.02% | 694 |
|
|
2018
Q2 | $56.6M | Sell |
77,328
-8,577
| -10% | -$9.89M | 0.02% | 918 |
|
|
2018
Q1 | $137M | Sell |
85,905
-45,752
| -35% | -$58.9M | 0.04% | 459 |
|
|
2017
Q4 | $118M | Sell |
131,657
-5,822
| -4% | -$3.44M | 0.03% | 546 |
|
|
2017
Q3 | $49.5M | Sell |
137,479
-5,096
| -4% | -$1.59M | 0.01% | 996 |
|
|
2017
Q2 | $41.8M | Buy |
142,575
+848
| +0.6% | +$245K | 0.01% | 1086 |
|
|
2017
Q1 | $49.9M | Buy |
141,727
+11,154
| +9% | +$2.51M | 0.01% | 960 |
|
|
2016
Q4 | $24M | Buy |
130,573
+8,902
| +7% | +$1.81M | 0.01% | 1422 |
|
|
2016
Q3 | $31.4M | Buy |
121,671
+3,738
| +3% | +$962K | 0.01% | 1163 |
|
|
2016
Q2 | $25.2M | Sell |
117,933
-9,973
| -8% | -$2.23M | 0.01% | 1259 |
|
|
2016
Q1 | $26.4M | Buy |
127,906
+3,278
| +3% | +$630K | 0.01% | 1232 |
|
|
2015
Q4 | $31.5M | Buy |
124,628
+5,792
| +5% | +$1.19M | 0.01% | 1091 |
|
|
2015
Q3 | $19.5M | Buy |
118,836
+20,105
| +20% | +$3.56M | 0.01% | 1421 |
|
|
2015
Q2 | $18.5M | Sell |
98,731
-66,230
| -40% | -$11.4M | 0.01% | 1537 |
|
|
2015
Q1 | $27.2M | Sell |
164,961
-63,528
| -28% | -$13.1M | 0.01% | 1274 |
|
|
2014
Q4 | $53.1M | Sell |
228,489
-8,143
| -3% | -$1.74M | 0.01% | 862 |
|
|
2014
Q3 | $42.8M | Buy |
236,632
+172
| +0.1% | +$32.9K | 0.01% | 959 |
|
|
2014
Q2 | $45.5M | Buy |
236,460
+3,558
| +2% | +$629K | 0.01% | 961 |
|
|
2014
Q1 | $42.3M | Buy |
232,902
+8,537
| +4% | +$1.69M | 0.01% | 993 |
|
|
2013
Q4 | $38.2M | Buy |
224,365
+50,828
| +29% | +$8.2M | 0.01% | 1040 |
|
|
2013
Q3 | $27.2M | Sell |
173,537
-25,444
| -13% | -$4.7M | 0.01% | 1203 |
|
|
2013
Q2 | $34.5M | Buy |
+198,981
| New | +$30.5M | 0.01% | 1033 |
|
Other funds holding NKTR
EA
EMFAT
BCM
SCM
NNPTE
ACL
Bank of New York Mellon's NKTR Position: Q2 2026 in Review
Bank of New York Mellon increased its Nektar Therapeutics (NKTR) stake by 1,356% in Q2 2026, buying an estimated $6.55M and bringing the position to 96,061 shares worth $6.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2265.
Bank of New York Mellon first reported a position in NKTR in Q2 2013 and has held it in 51 quarters since. The position peaked at $137M in Q1 2018. 82 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.
- Bank of New York Mellon held 96,061 shares of Nektar Therapeutics worth $6.71M as of Q2 2026.
- Bank of New York Mellon bought 89,464 Nektar Therapeutics shares in Q2 2026, an estimated $6.55M.
- Nektar Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2265 holding.
- Bank of New York Mellon first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Bank of New York Mellon's Nektar Therapeutics position peaked at $137M in Q1 2018.
- 82 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.